Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement